ERBB2 and breast cancer: Patients expressing the hyperactive 611-HER2-CTF isoform of p95HER2 (hereafter known as p95HER2) more frequently develop a metastatic form of breast cancer with a poor prognosis, compared to patients that only express the full-length HER2 receptor [14,15,22,23].